These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

430 related articles for article (PubMed ID: 32679860)

  • 1. Cytokine-Mediated Dysregulation of Signaling Pathways in the Pathogenesis of Multiple Myeloma.
    Akhtar S; Ali TA; Faiyaz A; Khan OS; Raza SS; Kulinski M; Omri HE; Bhat AA; Uddin S
    Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32679860
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Role of Marrow Microenvironment in the Growth and Development of Malignant Plasma Cells in Multiple Myeloma.
    Giannakoulas N; Ntanasis-Stathopoulos I; Terpos E
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33923357
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Cytokine profiles of multiple myeloma and Waldenström macroglobulinemia].
    Sedlaříková L; Sadílková K; Kubiczková L; Hájek R; Sevčíková S
    Klin Onkol; 2014; 27(1):18-23. PubMed ID: 24635433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular pathogenesis of multiple myeloma: chromosomal aberrations, changes in gene expression, cytokine networks, and the bone marrow microenvironment.
    Klein B; Seckinger A; Moehler T; Hose D
    Recent Results Cancer Res; 2011; 183():39-86. PubMed ID: 21509680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Repurposing tofacitinib as an anti-myeloma therapeutic to reverse growth-promoting effects of the bone marrow microenvironment.
    Lam C; Ferguson ID; Mariano MC; Lin YT; Murnane M; Liu H; Smith GA; Wong SW; Taunton J; Liu JO; Mitsiades CS; Hann BC; Aftab BT; Wiita AP
    Haematologica; 2018 Jul; 103(7):1218-1228. PubMed ID: 29622655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIF-1α inhibition blocks the cross talk between multiple myeloma plasma cells and tumor microenvironment.
    Borsi E; Perrone G; Terragna C; Martello M; Zamagni E; Tacchetti P; Pantani L; Brioli A; Dico AF; Zannetti BA; Rocchi S; Cavo M
    Exp Cell Res; 2014 Nov; 328(2):444-55. PubMed ID: 25257607
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Osteoclast Immunosuppressive Effects in Multiple Myeloma: Role of Programmed Cell Death Ligand 1.
    Tai YT; Cho SF; Anderson KC
    Front Immunol; 2018; 9():1822. PubMed ID: 30147691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pentraxin 3 (PTX3) inhibits plasma cell/stromal cell cross-talk in the bone marrow of multiple myeloma patients.
    Basile A; Moschetta M; Ditonno P; Ria R; Marech I; De Luisi A; Berardi S; Frassanito MA; Angelucci E; Derudas D; Specchia G; Curci P; Pavone V; Rossini B; Ribatti D; Bottazzi B; Mantovani A; Presta M; Dammacco F; Vacca A
    J Pathol; 2013 Jan; 229(1):87-98. PubMed ID: 22847671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myeloma plasma cells alter the bone marrow microenvironment by stimulating the proliferation of mesenchymal stromal cells.
    Noll JE; Williams SA; Tong CM; Wang H; Quach JM; Purton LE; Pilkington K; To LB; Evdokiou A; Gronthos S; Zannettino AC
    Haematologica; 2014 Jan; 99(1):163-71. PubMed ID: 23935020
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extracellular vesicle cross-talk in the bone marrow microenvironment: implications in multiple myeloma.
    Wang J; Faict S; Maes K; De Bruyne E; Van Valckenborgh E; Schots R; Vanderkerken K; Menu E
    Oncotarget; 2016 Jun; 7(25):38927-38945. PubMed ID: 26950273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bone marrow microenvironment and the progression of multiple myeloma.
    Caligaris-Cappio F; Gregoretti MG; Merico F; Gottardi D; Ghia P; Parvis G; Bergui L
    Leuk Lymphoma; 1992 Sep; 8(1-2):15-22. PubMed ID: 1493467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiple myeloma: signaling pathways and targeted therapy.
    Lu Q; Yang D; Li H; Niu T; Tong A
    Mol Biomed; 2024 Jul; 5(1):25. PubMed ID: 38961036
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Zoledronic acid exerts its antitumor effect in multiple myeloma interfering with the bone marrow microenvironment.
    Corso A; Ferretti E; Lazzarino M
    Hematology; 2005 Jun; 10(3):215-24. PubMed ID: 16019470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bone marrow microenvironment in multiple myeloma progression.
    Manier S; Sacco A; Leleu X; Ghobrial IM; Roccaro AM
    J Biomed Biotechnol; 2012; 2012():157496. PubMed ID: 23093834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple myeloma-initiating cells.
    Hosen N
    Int J Hematol; 2013 Mar; 97(3):306-12. PubMed ID: 23420183
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Growth factors and antiapoptotic signaling pathways in multiple myeloma.
    van de Donk NW; Lokhorst HM; Bloem AC
    Leukemia; 2005 Dec; 19(12):2177-85. PubMed ID: 16239913
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD28 expressed on malignant plasma cells induces a prosurvival and immunosuppressive microenvironment.
    Nair JR; Carlson LM; Koorella C; Rozanski CH; Byrne GE; Bergsagel PL; Shaughnessy JP; Boise LH; Chanan-Khan A; Lee KP
    J Immunol; 2011 Aug; 187(3):1243-53. PubMed ID: 21715687
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple myeloma: Implementing signaling pathways and molecular biology in clinical trials.
    Bazzi M; Badros A
    Cancer Biol Ther; 2010 Nov; 10(9):830-8. PubMed ID: 21045554
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiple myeloma: biology of the disease.
    Mahindra A; Hideshima T; Anderson KC
    Blood Rev; 2010 Nov; 24 Suppl 1():S5-11. PubMed ID: 21126636
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toward development of a novel NOD/SCID-based in vivo strategy to model multiple myeloma pathogenesis.
    Bueno C; Lopes LF; Greaves M; Menendez P
    Exp Hematol; 2007 Oct; 35(10):1477-8. PubMed ID: 17681665
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 22.